Summary
EudraCT Number: 2009-014602-33
Sponsor's Protocol Code Number: CH-2009.01
National Competent Authority: France - ANSM 
Clinical Trial Type: EEA CTA
Trial Status: Ongoing
Date on which this record was first entered in the EudraCT database: 2009-10-01
Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014602-33/FR/

A. Protocol Information
A.1 Member State Concerned: France - ANSM
A.2 EudraCT number: 2009-014602-33
A.3 Full title of the trial: IMPACT D’UNE INTENSIFICATION THERAPEUTIQUE PAR INHIBITEUR D’INTEGRASE +/- INHIBITEUR DE CCR5 SUR LE RESERVOIR LYMPHOÏDE DU VIH-1 CHEZ DES PATIENTS AU STADE CHRONIQUE DE L’INFECTION     
A.3.2 Name or abbreviated title of the trial where available: IntensVIH
A.4.1 Sponsor's protocol code number: CH-2009.01
A.7 Trial is part of a Paediatric Investigation Plan: Information not present in EudraCT
A.8 EMA Decision number of Paediatric Investigation Plan: 

B. Sponsor Information
Sponsor 1
B.1.1 Name of Sponsor: Centre Hospitalier Intercommunal de Toulon - La Seyne sur Mer
B.1.3.4	Country: France
B.3.1 and B.3.2	Status of the sponsor: Non-Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1 Name of organisation providing support:
B.4.2 Country:
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1 Name of organisation: 
B.5.2 Functional name of contact point: 

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: ISENTRESS
D.2.1.1.2 Name of the Marketing Authorisation holder: Merck Sharp & Dohme
D.2.1.2 Country which granted the Marketing Authorisation: United Kingdom
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: ISENTRESS
D.3.2 Product code: MK-0518
D.3.4 Pharmaceutical form: Tablet
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: RALTEGRAVIR
D.3.9.1 CAS number: 518048-05-0
D.3.10 Strength
D.3.10.1 Concentration unit: IU/mg international unit(s)/milligram
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 400 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 2
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: CELSENTRI limited
D.2.1.1.2 Name of the Marketing Authorisation holder: Pfizer
D.2.1.2 Country which granted the Marketing Authorisation: United Kingdom
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: CELSENTRI
D.3.4 Pharmaceutical form: Tablet
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: MARAVIROC
D.3.9.1 CAS number: 376348-65-1
D.3.10 Strength
D.3.10.1 Concentration unit: IU international unit(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 150 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No

D.8 Information on Placebo

E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1 Medical condition(s) being investigated: Infection à VIH-1
MedDRA Classification
E.1.3 Condition being studied is a rare disease: No
E.2 Objective of the trial
E.2.1 Main objective of the trial: Evaluer l’effet d’une intensification thérapeutique par un inhibiteur d’Integrase avec ou sans traitement inhibiteur du CCR5 au niveau du réservoir lymphoïde de patients infectés de façon chronique par le VIH-1 et en succès thérapeutique sous « trithérapie classique », mesuré par :
-la réplication plasmatique résiduelle entre 0 et 50 copies/ml
-les titres d’ARN du VIH intra-cellulaires dans les lymphocytes circulants (PBMC) et les lymphocytes du tissu lymphoïde associé au tractus digestif au niveau rectal (LR). 
-les titres d’ADN proviral du VIH dans les PBMC et les LR.


E.2.2 Secondary objectives of the trial: 1.	 Impact de ces stratégies sur le taux de CD4 circulants 
2.	Impact de ces stratégies sur le taux l’activation des CD8  
E.2.3 Trial contains a sub-study: No
E.3 Principal inclusion criteria: 1.	Patients de sexe masculin ou féminin, âgés de plus de 18 ans
2.	Confirmation de l’infection par le VIH par un Western Blot
3.	Indice de Karnofsky > 80% 
4.	Patients prétraités  par une combinaison anti-rétrovirale incluant au moins 2 RTI et 1 IP/r depuis au moins 12 mois avec virémie plasmatique <50 copies/ml depuis au moins 6 mois 
5.	Traitement de 1° ligne (ou tout autre ligne si les changements n’ont pas eu lieu pour des raisons de résistance virale) par 2 RTIs et 1 IP/r stable   
6.	Tolérance et observance correctes de la combinaison en cours ;
7.	Acceptation de la réalisation de 3 recto-sigmoïdoscopies sur 12 mois;
8.	ARN plasmatique du VIH-1 <50 copies/ml à l’inclusion ;
9.	CD4 circulants >200/mm3 à l’inclusion;
10.	Patients naïfs d’Isentress® et de Celsentri®
11.	Absence de contre-indication à la prise d’un des traitements de l’étude
12.	Consentement éclairé écrit, recueilli auprès du patient ou de son représentant légal.
E.4 Principal exclusion criteria: 1.	Infection opportuniste ou affection tumorale en évolution 
2.	Diarrhée chronique, malabsorption, infection entérique évolutive 
3.	Age inférieur à 18 ans 
4.	Grossesse – allaitement 
5.	Co-infection par le VIH-2 
6.	Antécédent de traitement immuno-modulateur (Interleukine 2, alpha-interféron) 
7.	Traitement d’une co-infection à VHB ou VHC en cours 
8.	Troubles de la crase sanguine 
9.	Contrindications à l’administration du Raltégravir ou du Maraviroc
10.	Nadir de CD4 circulants <100/mm3 au cours de l’histoire naturelle de l’infection à VIH-1.
E.5 End points
E.5.1 Primary end point(s): -la réplication plasmatique résiduelle entre 0 et 50 copies/ml
-les titres d’ARN du VIH intra-cellulaires dans les lymphocytes circulants (PBMC) et les lymphocytes du tissu lymphoïde associé au tractus digestif au niveau rectal (LR). 
-les titres d’ADN proviral du VIH dans les PBMC et les LR

E.6 and E.7 Scope of the trial
E.6 Scope of the Trial
E.6.1 Diagnosis: No
E.6.2 Prophylaxis: No
E.6.3 Therapy: Yes
E.6.4 Safety: No
E.6.5 Efficacy: No
E.6.6 Pharmacokinetic: No
E.6.7 Pharmacodynamic: No
E.6.8 Bioequivalence: No
E.6.9 Dose response: No
E.6.10 Pharmacogenetic: No
E.6.11 Pharmacogenomic: No
E.6.12 Pharmacoeconomic: No
E.6.13 Others: No
E.7 Trial type and phase 
E.7.1 Human pharmacology (Phase I): No
E.7.1.1 First administration to humans: No
E.7.1.2 Bioequivalence study: No
E.7.1.3 Other: No
E.7.1.3.1 Other trial type description: 
E.7.2 Therapeutic exploratory (Phase II): No
E.7.3 Therapeutic confirmatory (Phase III): Yes
E.7.4 Therapeutic use (Phase IV): No
E.8 Design of the trial
E.8.1 Controlled: Yes
E.8.1.1 Randomised: Yes
E.8.1.2 Open: Yes
E.8.1.3 Single blind: No
E.8.1.4 Double blind: No
E.8.1.5 Parallel group: Yes
E.8.1.6 Cross over: No
E.8.1.7 Other: No
E.8.2 Comparator of controlled trial
E.8.2.1 Other medicinal product(s): No
E.8.2.2 Placebo: No
E.8.2.3 Other: Yes
E.8.2.3.1 Comparator description: Avec Isentress pendant 12 mois ou,  pendant 6 mois ( 6 mois plus tard) +/- Celsentri
E.8.3 The trial involves single site in the Member State concerned: Yes
E.8.4 The trial involves multiple sites in the Member State concerned: No
E.8.5 The trial involves multiple Member States: No
E.8.6 Trial involving sites outside the EEA
E.8.6.1 Trial being conducted both within and outside the EEA: No
E.8.6.2 Trial being conducted completely outside of the EEA: Information not present in EudraCT
E.8.7 Trial has a data monitoring committee: No
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial: Date de la dernière visite de la dernière personne participant à l'essai
E.8.9 Initial estimate of the duration of the trial
E.8.9.1 In the Member State concerned years: 2
E.8.9.1 In the Member State concerned months: 0
E.8.9.1 In the Member State concerned days: 0
E.8.9.2 In all countries concerned by the trial years: 2
E.8.9.2 In all countries concerned by the trial months: 0
E.8.9.2 In all countries concerned by the trial days: 0

F. Population of Trial Subjects
F.1 Age Range
F.1.1 Trial has subjects under 18: No
F.1.1.1 In Utero: No
F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks): No
F.1.1.3 Newborns (0-27 days): No
F.1.1.4 Infants and toddlers (28 days-23 months): No
F.1.1.5 Children (2-11years): No
F.1.1.6 Adolescents (12-17 years): No
F.1.2 Adults (18-64 years): Yes
F.1.3 Elderly (>=65 years): Yes
F.2 Gender
F.2.1 Female: Yes
F.2.2 Male: Yes
F.3 Group of trial subjects
F.3.1 Healthy volunteers: No
F.3.2 Patients: Yes
F.3.3 Specific vulnerable populations: Yes
F.3.3.1 Women of childbearing potential not using contraception : No
F.3.3.2 Women of child-bearing potential using contraception: Yes
F.3.3.3 Pregnant women: No
F.3.3.4 Nursing women: No
F.3.3.5 Emergency situation: No
F.3.3.6 Subjects incapable of giving consent personally: No
F.3.3.7 Others: No
F.4 Planned number of subjects to be included
F.4.1 In the member state: 35
F.4.2 For a multinational trial
F.4.2.1 In the EEA: 35
F.4.2.2 In the whole clinical trial: 35
F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition): Poursuite du traitement anti retroviral initial selon les souhait de l’investigateur

G. Investigator Networks to be involved in the Trial


N. Review by the Competent Authority or Ethics Committee in the country concerned
N. Competent Authority Decision: Authorised
N. Date of Competent Authority Decision: 2009-11-17
N. Ethics Committee Opinion of the trial application: Favourable
N. Ethics Committee Opinion: Reason(s) for unfavourable opinion:
N. Date of Ethics Committee Opinion: 2010-06-03

P. End of Trial
P. End of Trial Status: Ongoing

